Aktis Oncology, Inc.
AKTS
$18.75
$0.030.16%
NASDAQ
| 12/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | 100.43% | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | 100.43% | ||||
| Cost of Revenue | 30.83% | ||||
| Gross Profit | -25.27% | ||||
| SG&A Expenses | -30.54% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 16.16% | ||||
| Operating Income | -11.13% | ||||
| Income Before Tax | -25.56% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -25.56% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -25.56% | ||||
| EBIT | -11.13% | ||||
| EBITDA | -9.78% | ||||
| EPS Basic | -13.41% | ||||
| Normalized Basic EPS | -13.41% | ||||
| EPS Diluted | -13.41% | ||||
| Normalized Diluted EPS | -13.41% | ||||
| Average Basic Shares Outstanding | 10.72% | ||||
| Average Diluted Shares Outstanding | 10.72% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||